Angelika Eggert

Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells.

Resistance to chemotherapy mediated by TrkB in neuroblastomas.

Apoptosis induction by TRAIL.

Angiogenic cytokines. Quantitative and functional analysis.

The Phox2B homeobox gene is mutated in sporadic neuroblastomas.

Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas.

Identification of dynamic proteome changes upon ligand activation of Trk-receptors using two-dimensional fluorescence difference gel electrophoresis and mass spectrometry.

Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.

Application of microarray-based technology to neuroblastoma.

Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma.

The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness.

Phox2B mutations and the Delta-Notch pathway in neuroblastoma.

Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.

VEGF plasma levels in non-ruptured intracranial aneurysms.

Vascular endothelial growth factor plasma levels are significantly elevated in patients with cerebral arteriovenous malformations.

Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia.

Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes.

High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors.

Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome.

Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.

The mutagenic potential of non-homologous end joining in the absence of the NHEJ core factors Ku70/80, DNA-PKcs and XRCC4-LigIV.

ArrayCGH-based classification of neuroblastoma into genomic subgroups.

MYCN regulates oncogenic MicroRNAs in neuroblastoma.

Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics.

Neurotrophin receptor expression in human primary retinoblastomas and retinoblastoma cell lines.

Neuroblastoma: biology, prognosis, and treatment.

Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.

Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy.

CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23.

Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines.

Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells.

MicroRNAs in the pathogenesis of neuroblastoma.

Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells.

The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo.

Overall genomic pattern is a predictor of outcome in neuroblastoma.

Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.

Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction.

Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds.

Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma.

Neuroblastoma: biology, prognosis, and treatment.

IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.

Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.

Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma.

Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma.

Accurate prediction of neuroblastoma outcome based on miRNA expression profiles.

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors.

A small kiss of death for cancer.

Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.

Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.

High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.

Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.

Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.

miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.

The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma.

[In Process Citation].